ClinicalTrials.gg
CompletedNCT07004504MECHANISMUpdated Mar 25, 2026

MEnstrual Cycle pHase ANd dIabeteS Management

An observational study in Type 1 Diabetes Mellitus, sponsored by DCB Research AG. Completed at 1 site in Switzerland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by DCB Research AG · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
77
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.

Enrollment
9th of 18
77 · median 73
Started
2023
with 6 others
Observational
18 of 70
4 open now
Registered
65th of 70
by date
Lead sponsor
3 of 70
DCB Research AG

Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 9th largest by enrollment of the 18 observational ones that give a count, is one of 7 that started in 2023, is one of 18 observational ones, and was the 65th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, or all of them as a file.
02

Study summary

This study evaluates the impact of menstrual cycle phases on insulin sensitivity, glycaemic control, and insulin requirements in women with type 1 diabetes (T1D). It aims to quantify differences between the follicular and luteal phases using data from the Tidepool Data Platform. Key endpoints include modelled insulin sensitivity, mean glucose, Time in Range (TIR), and total insulin dose.

Secondary objectives include assessing phase-specific variability in the endpoints and differences between participants.

The study follows a decentralized, anonymized data collection approach, with participants using continuous glucose monitors (CGMs) and insulin pumps or smart pens. Glycaemic outcomes and insulin requirements will be compared across menstrual cycle phases using linear mixed-effects models to account for repeated measures within individuals. Cycle phase-specific variation in insulin sensitivity will be quantified using a hierarchical Bayesian state-space model, which estimates a latent insulin sensitivity parameter from CGM time series data while accounting for measurement noise and temporal dynamics.

The findings are expected to improve understanding of glycaemic dynamics across the menstrual cycle and inform future diabetes management strategies.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Insulin sensitivity
  • Menstrual cycle
  • Diabetes management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study includes adults (18+) living with type 1 diabetes (T1D) who use a continuous glucose monitoring (CGM) system and either an insulin pump or a smart pen for insulin delivery. Participants must be willing to upload diabetes-related data to the Tidepool Data Platform, track and share their menstrual cycle data, and provide consent for their anonymized data to be used in research.

Eligibility criteria

Inclusion criteria

People are eligible to participate in the study if they:

  • are living with T1D;
  • are willing to upload diabetes-related data to the Tidepool Data Platform;
  • are using a continuous glucose monitoring (CGM) system;
  • are using an insulin pump or a smart pen for most of their insulin delivery;
  • are willing to track and share their menstrual cycle data;
  • are 18 years old or older;
  • give consent to share their anonymized data for research.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
77 participants (actual)
Patient registry
No

Groups and cohorts

  • Single Arm

    The study cohort consists of women with type 1 diabetes (T1D) who use continuous glucose monitoring (CGM) and insulin pumps to manage their diabetes. Participants will anonymously upload their diabetes management data, along with self-reported menstrual cycle information.

06

What researchers measure

Primary outcomes

  1. Insulin sensitivity

    Insulin sensitivity quantified by using a hierarchical Bayesian state-space model that estimates a latent insulin sensitivity parameter from CGM time series data.

    Time frame: Between 1 and 12 months

Secondary outcomes

  1. Mean glucose

    Mean daily glucose based on CGM data

    Time frame: Between 1 and 12 months

  2. Time in range (TIR)

    Mean daily TIR based on CGM data

    Time frame: Between 1 and 12 months

  3. Time above range (TAR)

    Mean daily TAR based on CGM data

    Time frame: Between 1 and 12 months

  4. Time belwo range (TBR)

    Mean daily TBR based on CGM data

    Time frame: Between 1 and 12 months

  5. Total daily insulin

    Mean daily total insulin based on insulin pump data

    Time frame: Between 1 and 12 months

  6. Total basal insulin

    Mean daily total basal insulin based on insulin pump data

    Time frame: Between 1 and 12 months

  7. Total bolus insulin

    Mean daily total bolus insulin based on insulin pump data

    Time frame: Between 1 and 12 months

07

Study locations

1 site
  • DCB Research AG
    Bern, 3010, Switzerland
08

References and documents

Publications

  • Schiavon M, Dalla Man C, Kudva YC, Basu A, Cobelli C. Quantitative estimation of insulin sensitivity in type 1 diabetic subjects wearing a sensor-augmented insulin pump. Diabetes Care. 2014;37(5):1216-23. doi: 10.2337/dc13-1120. Epub 2013 Dec 6. PubMed 24319120 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Dec 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Jun 4, 2025
StartActual
Dec 14, 2023
Primary completionActual
Dec 29, 2024
CompletionActual
Dec 29, 2024
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07004504
Lead sponsor
DCB Research AG
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Dec 14, 2023
Primary completion
Dec 29, 2024
Completion
Dec 29, 2024
Last update
Mar 25, 2026

Study contacts

Martina Rothenbühler, PhD
principal investigator · DCB Research AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion